OKYO Pharma Files Form 6‑K on Apr 7, 2026 OKYO Pharma filed a Form 6‑K on Apr 7, 2026 (Investing.com timestamp 11:20:51 GMT); content, not form, will determine market impact and execution risk.

OKYO Pharma Files Form 6‑K on Apr 7, 2026: OKYO Pharma filed a Form 6‑K on Apr 7, 2026 (Investing.com timestamp 11:20:51 GMT); content, not form, will determine market impact and execution risk. 👈 Read full analysis #OKYOPharma #Form6K #Biotech #Investing #MarketImpact

#OKYO
#OkyoPharma just reported positive Phase 2 results in neuropathic corneal pain, a chronic eye condition with no FDA-approved treatment.
75% of patients saw over 80% pain reduction with urcosimod, showing strong potential in a truly underserved space.
prismmarketview.com/okyo-pharma-...